Search Results

Schihada Following studies in Pharmacy in Regensburg, Germany, I joined the receptor pharmacology group of Martin Lohse at the Institute of Pharmacology & Toxicology in Würzburg, Germany, in 2015.

During my PhD studies in Martin Lohse lab at the Max Delbrueck Center in Berlin, I consolidated my knowledge

<< Back to podcast list Strategic Partner(s) Martin Audet About Dr. Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke Martin Audet on the web LinkedIn Twitter Sherbrooke University Google Scholar Dr.

Jean Martin Beaulieu About Dr. Jean Martin Beaulieu Dr. Jean Martin Beaulieu on the web University of Toronto Google Scholar LinkedIn ResearchGate Dr.

Explore Martin Marro’s impact on GPCR drug discovery, assay innovation, and translational pharmacology Martin Marro, currently Executive Director and Head of Cell Pharmacology at Eli Lilly’s Obesity Research About Martin Marro Dr. Martin Marro leads the Cell Pharmacology group in the Diabetes, Obesity and Complications Therapeutic

Instructors at the course included Marc Chabre , Harden McConnell , Richard Henderson , Martin Rodbell , Jean-Pierre Changeux , and Martin Karplus .

Martine Smit . During his Ph.D., Timo, together with Dr.

Jean Martin Beaulieu (2003) Dr. Laura Bohn (1999) Dr. Kathleen Caron - Co-host- (1970) Dr.

in Molecular Pharmacology at Monash University, then trained in single-cell biology as an NHMRC CJ Martin

gripping conversation, Catherine, a PhD candidate at the University of Michigan, shares how personal loss How loss and lived experience can sharpen scientific focus. But loss has a way of sharpening focus—friends lost to overdose brought the opioid epidemic into painful

Ecosystem.DrGPCR.com shall not be responsible or liable, directly or indirectly, for any damage or loss the third party, and the Customer agrees that Ecosystem.DrGPCR.com shall not be held liable for any loss is not liable, and Customer agrees not to hold Ecosystem.DrGPCR.com responsible, for any damages or losses (including, but not limited to, loss of money, goodwill or reputation, profits, or other intangible attorneys, advertisers, product and service providers, and affiliates harmless from any liability, loss

the most drugged protein family in medicine, but until recently their role in cancer was treated as marginal In knockout mice, loss of CXCR3 abolishes response to both anti-PD-1 and anti-CTLA-4, reframing the receptor

He discovered multiple rare and loss-of-function variants of the MT2 melatonin receptors that are associated

look at what it means to modulate opioid pharmacology downstream of the receptor — and why the safety margins

Gutkind — carrying a personal loss in New York and leading a cancer center building that operated at

a disease of signaling imbalance: an overdrive of AT1R activation by angiotensin II, paired with a loss

knockout cell is intrinsically different from the wild-type — complicating any conclusions drawn from loss-of-function

Have a Fundamental Limitation Traditional β₂-adrenergic agonists can stimulate muscle growth and fat loss